Reminyl

How to order Reminyl

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Reminyl on Prescriptsy

Reminyl is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Reminyl is the brand name for galantamine, a medicine used to treat the symptoms of mild to moderately severe Alzheimer's disease.

Galantamine is a dual-action cholinergic agent that works by inhibiting the enzyme acetylcholinesterase (AChE) and allosterically modulating nicotinic acetylcholine receptors in the brain.

This dual mechanism increases the availability of acetylcholine at cholinergic synapses and enhances nicotinic receptor function, improving cognitive performance, attention, and functional ability.

Reminyl is available as immediate-release tablets, prolonged-release capsules, and an oral solution.

It is a prescription-only medicine (POM) in the UK, manufactured by Janssen (part of Johnson and Johnson).

Alzheimer's disease is the most common cause of dementia, accounting for approximately 60% to 70% of all dementia cases.

In the UK, an estimated 900,000 people live with dementia, and this number is projected to exceed 1.5 million by 2040.

Alzheimer's disease is a progressive neurodegenerative disorder characterised by the accumulation of amyloid-beta plaques and neurofibrillary tangles composed of hyperphosphorylated tau protein in the brain.

These pathological changes lead to widespread neuronal loss, particularly in the cholinergic system, which is essential for memory, learning, and attention.

The cholinergic hypothesis of Alzheimer's disease proposes that much of the cognitive decline observed in the condition results from deficient cholinergic neurotransmission.

This page provides a comprehensive clinical guide to Reminyl, including how it works, dosage instructions, side effects, safety warnings, and how to obtain a prescription in the United Kingdom.

Important safety information about Reminyl

Before reading further, please note these essential safety points.

• Reminyl should be initiated and supervised by a specialist experienced in diagnosing and treating Alzheimer's disease.
• The dose must be increased gradually over at least 8 weeks to minimise gastrointestinal side effects. Do not skip dose titration steps.
• Galantamine may cause bradycardia (slow heart rate). Caution is required in patients with cardiac conduction disorders or those taking heart rate-lowering medicines.
• Anticholinergic medicines (commonly prescribed for bladder symptoms and as certain antidepressants) may reduce the effectiveness of galantamine and should be reviewed.
• Treatment should be reviewed at least every 6 months. Galantamine should be continued only while there is evidence of clinical benefit.

Understanding Alzheimer's disease

Alzheimer's disease typically presents with progressive memory loss, initially affecting short-term and episodic memory, followed by declining language ability, visuospatial skills, and executive function.

Behavioural and psychological symptoms of dementia (BPSD), including agitation, anxiety, depression, apathy, and sleep disturbance, are common and often more distressing for carers than the cognitive symptoms.

The disease progresses through stages: in mild Alzheimer's, the person may have difficulty remembering recent events, finding words, or managing complex tasks such as finances.

In moderate Alzheimer's, increasing support is needed with daily activities such as dressing, cooking, and personal hygiene.

In severe Alzheimer's, the person becomes dependent on carers for all activities of daily living.

The cholinergic system, centred on the nucleus basalis of Meynert in the basal forebrain, is among the earliest and most severely affected neural circuits in Alzheimer's disease.

Cholinergic neurones project widely throughout the cerebral cortex and hippocampus, modulating attention, memory encoding, and consolidation.

The loss of these neurones and the resulting deficit in acetylcholine underpin many of the cognitive symptoms of the disease.

Cholinesterase inhibitors such as galantamine aim to boost remaining cholinergic function by preventing the breakdown of acetylcholine, thereby partially compensating for neuronal loss.

How Reminyl works

Galantamine has a unique dual mechanism of action among the cholinesterase inhibitors used to treat Alzheimer's disease.

Its primary action is the reversible competitive inhibition of AChE, which slows the enzymatic hydrolysis of acetylcholine in the synaptic cleft.

This increases the concentration and duration of action of acetylcholine at both muscarinic and nicotinic receptors.

The inhibition is reversible, meaning that galantamine dissociates from the enzyme over time, and its effect is dependent on continued drug administration.

Its secondary action is the allosteric potentiating modulation of nicotinic acetylcholine receptors (nAChRs), particularly the alpha-4 beta-2 and alpha-7 subtypes.

Galantamine binds to an allosteric site on the nicotinic receptor, distinct from the acetylcholine binding site, and potentiates the response to acetylcholine.

This means that when acetylcholine binds to the receptor, the ion channel opens more readily and for longer, enhancing cholinergic neurotransmission.

Nicotinic receptor modulation may also promote the release of other neurotransmitters, including glutamate, serotonin, and noradrenaline, potentially contributing to broader cognitive and behavioural effects.

Compared with the other AChE inhibitors available in the UK (donepezil and rivastigmine), galantamine is the only one with this additional nicotinic receptor-modulating property.

Donepezil is a selective, reversible AChE inhibitor without nicotinic activity. Rivastigmine is a pseudo-irreversible inhibitor of both AChE and butyrylcholinesterase (BuChE).

NICE technology appraisal TA217 recommends all three AChE inhibitors as options for mild to moderately severe Alzheimer's disease and does not preferentially recommend one over another.

The choice between them is based on individual tolerability, formulation preference, dosing convenience, and side-effect profile.

Clinical evidence for Reminyl

The efficacy of galantamine in Alzheimer's disease has been demonstrated in multiple large, multicentre, randomised, double-blind, placebo-controlled trials.

The pivotal GAL-INT-1 and GAL-INT-2 studies showed statistically significant improvements in cognition (measured by the ADAS-Cog scale), global function (CIBIC-plus), and activities of daily living (DAD scale) in patients treated with galantamine 16 to 24 mg per day compared with placebo over 5 to 6 months.

Response rates (defined as at least a 4-point improvement on ADAS-Cog) were approximately 30% to 40% for galantamine compared with 15% to 20% for placebo.

Long-term observational studies suggest that galantamine may slow the rate of cognitive and functional decline over 12 to 36 months, although the underlying disease continues to progress.

A meta-analysis by the Cochrane Collaboration confirmed that galantamine provides statistically significant benefits in cognition, global assessment, and daily function in Alzheimer's disease, with a number needed to treat (NNT) of approximately 7 to 12 for a clinically meaningful cognitive response.

NICE TA217 (updated 2011) recommends galantamine (along with donepezil and rivastigmine) as options for managing mild to moderately severe Alzheimer's disease (MMSE score approximately 10 to 26).

Treatment should only be continued when it is considered to be having a worthwhile effect on cognitive, global, functional, or behavioural symptoms.

Regular review by a specialist team is essential.

Dosage and administration

Galantamine should be started at a low dose and titrated gradually to reduce the risk of gastrointestinal side effects.

For immediate-release tablets, start with 4 mg twice daily with food for at least 4 weeks, then increase to 8 mg twice daily for at least 4 weeks, then consider 12 mg twice daily if appropriate.

For prolonged-release capsules, start with 8 mg once daily in the morning with food for at least 4 weeks, then increase to 16 mg once daily, then consider 24 mg once daily.

Prolonged-release capsules should be swallowed whole. The oral solution is dosed using the measuring syringe provided.

If treatment is interrupted for more than 3 days, restart at the lowest dose and re-titrate.

Side effects of Reminyl

Common side effects

Nausea and vomiting are the most common side effects and occur most often during dose titration.

Taking galantamine with food and following the recommended slow titration schedule significantly reduces these effects. Diarrhoea, decreased appetite, and weight loss are also common.

Weight should be monitored regularly in elderly patients with dementia. Dizziness, headache, drowsiness, and fatigue may occur.

Cardiovascular effects

Bradycardia is a recognised cholinergic effect. Galantamine may slow the heart rate by increasing vagal tone.

This is usually mild but can be clinically significant in patients with pre-existing cardiac conduction disorders or in combination with other rate-limiting medicines such as beta-blockers, digoxin, or non-dihydropyridine calcium channel blockers.

Syncope has been reported and may be related to bradycardia, orthostatic hypotension, or a combination of factors.

Falls are a recognised risk in elderly patients and may be multifactorial.

Other effects

Insomnia, vivid dreams, and agitation have been reported. Muscle cramps are a cholinergic effect. Urinary incontinence may occur. Rarely, seizures, hepatotoxicity, and severe skin reactions have been reported.

Report suspected adverse reactions to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk .

Warnings and precautions

Cardiac caution

An ECG should be considered before starting galantamine in patients with a history of cardiac disease, syncope, or conduction abnormalities. Monitor pulse rate during treatment.

Caution is required in patients with sick sinus syndrome, AV block, or those taking medicines that prolong the QT interval.

Gastrointestinal caution

Cholinesterase inhibitors increase gastric acid secretion. Use galantamine with caution in patients with active peptic ulcer disease or a history of gastrointestinal bleeding. Concurrent proton pump inhibitor therapy may be appropriate.

Drug interactions

Anticholinergic medicines (commonly prescribed for urinary symptoms, allergies, and as certain antidepressants) pharmacologically oppose the effect of galantamine and should be reviewed.

CYP2D6 and CYP3A4 inhibitors may increase galantamine levels.

Concurrent use with succinylcholine-type muscle relaxants may result in exaggerated neuromuscular blockade during anaesthesia; inform the anaesthetist that the patient takes galantamine.

Renal and hepatic impairment

Dose adjustment is required in moderate renal or hepatic impairment (maximum 16 mg/day). Galantamine should not be used in severe renal or severe hepatic impairment.

Supporting the person with Alzheimer's disease

Medication is only one aspect of dementia care.

NICE guideline NG97 recommends a holistic, person-centred approach that includes structured group cognitive stimulation therapy, social engagement, physical activity, and carer support.

Carers should be offered information, advice, and referral to local carer support services.

Lasting power of attorney and advance care planning should be discussed early in the disease course.

The Alzheimer's Society and Age UK provide valuable support and information for people living with dementia and their families in the UK.

How to get Reminyl in the UK

Reminyl (galantamine) is available on NHS prescription, initiated by a specialist in dementia care. Generic galantamine is also available and is routinely prescribed on the NHS.

NICE TA217 supports the use of galantamine for mild to moderately severe Alzheimer's disease.

The standard NHS prescription charge in England is 9.90 pounds per item; prescriptions are free in Scotland, Wales, and Northern Ireland.

Prepayment certificates are available for patients who need multiple prescription items.

Sources

• Reminyl XL, Summary of Product Characteristics (EMC)
• Galantamine, British National Formulary (BNF)
• NICE TA217: Donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease
• NICE NG97: Dementia, assessment, management, and support
• Alzheimer's disease, NHS
• Alzheimer's Society
• MHRA Yellow Card Scheme